Learn About Acute Myelomonocytic Leukemia

What is the definition of Acute Myelomonocytic Leukemia?
A rare acute myeloid leukemia disorder characterized by increased blast cells (myeloblasts, monoblast, and/or promonoblasts), representing more than 20% of the total bone marrow (BM) or peripheral blood differential counts, with 20-80% of BM cells being of monocytic lineage. Clinical presentation is the result of bone marrow involvement and extramedullary infiltration by the leukemic cells and includes asthenia, pallor, fever, dizziness, respiratory symptoms, easy bruising, bleeding disorders, and neurological deficits. Gingival hyperplasia, organomegaly, especially hepatosplenomegaly, and lymphadenopathy may also be associated.
Save information for later
Sign Up
What are the alternative names for Acute Myelomonocytic Leukemia?
  • Acute myelomonocytic leukemia
  • Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
  • AML M4
  • AML-M4
  • AMMoL
  • Acute myeloblastic leukemia type 4
  • AML with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
  • AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)
  • Acute myelomonocytic leukemia
  • CBFB-MYH11
Who are the top Acute Myelomonocytic Leukemia Local Doctors?
TK
Dr. Tapan M. Kadia
Oncology | Hematology Oncology | Hematology
Elite
Highly rated in
32
conditions
Oncology
Hematology Oncology
Hematology

University of Texas System

Physicians Referral Service

1515 Holcombe Blvd 
Houston, TX 77030

Tapan Kadia is an Oncologist and a Hematologist Oncology doctor in Houston, Texas. Dr. Kadia has been practicing medicine for over 21 years and is rated as an Elite doctor by MediFind in the treatment of Acute Myelomonocytic Leukemia. He is also highly rated in 32 other conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia, Myelodysplastic Syndrome MDS, Leukemia, and Acute Myeloblastic Leukemia with Maturation. He is licensed to treat patients in Texas. Dr. Kadia is currently accepting new patients.

View Profile
MP
Dr. Mrinal M. Patnaik
Hematology | Hematology Oncology
Elite
Highly rated in
38
conditions
Hematology
Hematology Oncology

Mayo Clinic

Rochester, Minnesota

200 1st St Sw 
Rochester, MN 55905

Mrinal Patnaik is a Hematologist and a Hematologist Oncology doctor in Rochester, Minnesota. Dr. Patnaik has been practicing medicine for over 22 years and is rated as an Elite doctor by MediFind in the treatment of Acute Myelomonocytic Leukemia. He is also highly rated in 38 other conditions, according to our data. His top areas of expertise are Chronic Myelomonocytic Leukemia, Acute Myelomonocytic Leukemia, Leukemia, and Myeloproliferative Neoplasms. He is licensed to treat patients in Minnesota. Dr. Patnaik is currently accepting new patients.

View Profile
 
 
 
 
Learn about our expert tiers
Learn more
HK
Hagop M. Kantarjian
Dr. Hagop M. Kantarjian
Hematology Oncology | Oncology | Hematology
Elite
Highly rated in
53
conditions
Hematology Oncology
Oncology
Hematology

University of Texas System

Physicians Referral Service

1515 Holcombe Blvd 
Houston, TX 77030

Hagop Kantarjian is a Hematologist Oncology specialist and an Oncologist in Houston, Texas. Dr. Kantarjian has been practicing medicine for over 43 years and is rated as an Elite doctor by MediFind in the treatment of Acute Myelomonocytic Leukemia. He is also highly rated in 53 other conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, Leukemia, and Myelodysplastic Syndrome MDS. He is licensed to treat patients in Texas. Dr. Kantarjian is currently accepting new patients.

View Profile
View All Doctors
What are the latest Acute Myelomonocytic Leukemia Clinical Trials?
Salsalate + Venetoclax/Decitabine for Patients With Acute Myelogenous Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
Who is this study for: Adult patients with Acute Myeloid Leukemia
Status: Recruiting
Start Date: October 26, 2020
Intervention Type: Drug
Study Drugs: Venetoclax, Decitabine, Azacitidine, Salsalate
Phase: Phase 2
View Trial
Summary: This phase II trial studies the side effects of salsalate when added to venetoclax and decitabine or azacitidine in treating patients with acute myeloid leukemia or myelodysplasia/myeloproliferative disease that has spread to other places in the body (advanced). Drugs used in chemotherapy, such as salsalate, venetoclax, decitabine, and azacitidine work in different ways to stop the growth of cance...
Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase Ib/II Study of APG-115 Alone or in Combination With Azacitidine in Patients With Relapse/Refractory AML, CMML or MDS
Who is this study for: Adult patients with Acute Myeloid Leukemia
Status: Recruiting
Start Date: December 4, 2020
Intervention Type: Drug
Study Drugs: Azacitidine
Phase: Phase 1/Phase 2
View Trial
Summary: This is a two Part study in patients with relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), or high risk myelodysplastic syndrome (MDS) that will initially evaluate the safety and tolerability of APG-115 as a single agent in Part 1, followed by a combination of APG-115 + 5-azacitidine (5-AZA) in Part 2.
View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

What are the Latest Advances for Acute Myelomonocytic Leukemia?
Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies.
Condition: Adults with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Journal: BMC cancer
Treatment Used: Volasertib Plus Azacitidine
Number of Patients: 22
Published: May 21, 2022
View publication
Summary: Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies.
Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation.
Condition: High-Risk Myeloid Malignancies
Journal: Annals of hematology
Treatment Used: Single-Agent 5-Azacytidine (AZA)
Number of Patients: 185
Published: March 30, 2022
View publication
Summary: Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation.
Tired of the same old research?
Check Latest Advances
Successful treatment with gilteritinib for relapsed acute myeloid leukemia with FLT3-N676K mutation.
Condition: Relapsed Acute Myeloid Leukemia
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Treatment Used: Gliteritinib
Number of Patients: 1
Published: February 09, 2022
View publication
Summary: Successful treatment with gilteritinib for relapsed acute myeloid leukemia with FLT3-N676K mutation.
View All Latest Advances